Cargando…

Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro

BACKGROUND: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous Platelet-Rich Plasma (PRP). METHODS: One hundred thirty-seven consecutive...

Descripción completa

Detalles Bibliográficos
Autores principales: Dallaudiere, B., Crombé, A., Gadeau, A. P., Pesquer, L., Peuchant, A., James, C., Silvestre, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206314/
https://www.ncbi.nlm.nih.gov/pubmed/30374787
http://dx.doi.org/10.1186/s40634-018-0162-4
_version_ 1783366349369638912
author Dallaudiere, B.
Crombé, A.
Gadeau, A. P.
Pesquer, L.
Peuchant, A.
James, C.
Silvestre, A.
author_facet Dallaudiere, B.
Crombé, A.
Gadeau, A. P.
Pesquer, L.
Peuchant, A.
James, C.
Silvestre, A.
author_sort Dallaudiere, B.
collection PubMed
description BACKGROUND: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous Platelet-Rich Plasma (PRP). METHODS: One hundred thirty-seven consecutive patients with symptomatic femoral-patellar osteoarthritis were included. All were addressed to our institution for a fluoroscopy-guided intra-articular PRP infiltration of the pathological femoral-patellar joint. For each patient, 500 μl of PRP were sampled before intra-articular injection. First, PRP samples were mixed with 50 μl of 2 widely used ICA: Visipaque270® (Iodixanol, n = 58) and Iopamiron200® (Iopamidol, n = 69). PRP concentration ([PRP]) was measured at different delays of incubation (t = 0, 5, 10, 15, 20 and 30 min) enabling to calculate PRP ratio (defined as [PRP](t)/[PRP](0mn)) at each delay, for each mixture, in order to quantitatively assess the influence of ICA on PRP ratio. Second, the PRP samples of 10 additional patients were mixed with Visipaque270®, Visipaque270®, Iopamiron200® and phosphate buffer saline (PBS: control solution) in order to qualitatively assess the influence of ICA on platelet aggregation, using ADP, Collagen, Arachidonic acid and TRAP tests. The surface expression of human P-selectin, a marker of α-granule release, in the PRP + Visipaque270® and PRP + Iopamiron200® mixtures was finally compared. Repeated-measures ANOVA, classical 2-way ANOVA and Wilcoxon matched-pairs test were used to study the influence of ICA on PRP quality. RESULTS: There was no significant change in PRP ratio during the first 30mn of incubation (p = 0.991) whatever the ICA (p = 0.926). Whatever the aggregation test, there was no significant difference in the percentage of platelet aggregation between PRP + PBS, PRP + Visipaque270® and PRP + Iopamiron200® (p = 0.998), nor between PRP + PBS and PRP + Visipaque320® (p = 0.470). Finally, there was no significant difference in P-selectin expression between the PRP + Visipaque270® and PRP + Iopamiron200® mixtures (p = 0.500). CONCLUSION: At early delays of incubation, Visipaque® and Iopamiron®, which are two widely used ICA for intra-articular infiltrations, did not influence the in vitro platelet function nor the quality of PRP.
format Online
Article
Text
id pubmed-6206314
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-62063142018-11-09 Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro Dallaudiere, B. Crombé, A. Gadeau, A. P. Pesquer, L. Peuchant, A. James, C. Silvestre, A. J Exp Orthop Research BACKGROUND: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous Platelet-Rich Plasma (PRP). METHODS: One hundred thirty-seven consecutive patients with symptomatic femoral-patellar osteoarthritis were included. All were addressed to our institution for a fluoroscopy-guided intra-articular PRP infiltration of the pathological femoral-patellar joint. For each patient, 500 μl of PRP were sampled before intra-articular injection. First, PRP samples were mixed with 50 μl of 2 widely used ICA: Visipaque270® (Iodixanol, n = 58) and Iopamiron200® (Iopamidol, n = 69). PRP concentration ([PRP]) was measured at different delays of incubation (t = 0, 5, 10, 15, 20 and 30 min) enabling to calculate PRP ratio (defined as [PRP](t)/[PRP](0mn)) at each delay, for each mixture, in order to quantitatively assess the influence of ICA on PRP ratio. Second, the PRP samples of 10 additional patients were mixed with Visipaque270®, Visipaque270®, Iopamiron200® and phosphate buffer saline (PBS: control solution) in order to qualitatively assess the influence of ICA on platelet aggregation, using ADP, Collagen, Arachidonic acid and TRAP tests. The surface expression of human P-selectin, a marker of α-granule release, in the PRP + Visipaque270® and PRP + Iopamiron200® mixtures was finally compared. Repeated-measures ANOVA, classical 2-way ANOVA and Wilcoxon matched-pairs test were used to study the influence of ICA on PRP quality. RESULTS: There was no significant change in PRP ratio during the first 30mn of incubation (p = 0.991) whatever the ICA (p = 0.926). Whatever the aggregation test, there was no significant difference in the percentage of platelet aggregation between PRP + PBS, PRP + Visipaque270® and PRP + Iopamiron200® (p = 0.998), nor between PRP + PBS and PRP + Visipaque320® (p = 0.470). Finally, there was no significant difference in P-selectin expression between the PRP + Visipaque270® and PRP + Iopamiron200® mixtures (p = 0.500). CONCLUSION: At early delays of incubation, Visipaque® and Iopamiron®, which are two widely used ICA for intra-articular infiltrations, did not influence the in vitro platelet function nor the quality of PRP. Springer Berlin Heidelberg 2018-10-29 /pmc/articles/PMC6206314/ /pubmed/30374787 http://dx.doi.org/10.1186/s40634-018-0162-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Dallaudiere, B.
Crombé, A.
Gadeau, A. P.
Pesquer, L.
Peuchant, A.
James, C.
Silvestre, A.
Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
title Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
title_full Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
title_fullStr Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
title_full_unstemmed Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
title_short Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
title_sort iodine contrast agents do not influence platelet-rich plasma function at an early time point in vitro
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206314/
https://www.ncbi.nlm.nih.gov/pubmed/30374787
http://dx.doi.org/10.1186/s40634-018-0162-4
work_keys_str_mv AT dallaudiereb iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro
AT crombea iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro
AT gadeauap iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro
AT pesquerl iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro
AT peuchanta iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro
AT jamesc iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro
AT silvestrea iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro